News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
856,407 Results
Type
Article (87126)
Company Profile (704)
Press Release (768557)
Multimedia
Podcasts (160)
Webinars (21)
Section
Business (232938)
Career Advice (4136)
Deals (39774)
Drug Delivery (132)
Drug Development (91166)
Employer Resources (200)
FDA (18231)
Job Trends (17378)
News (397094)
Policy (39872)
Tag
Academia (3002)
Academic (2)
Accelerated approval (16)
Adcomms (33)
Allergies (111)
Alliances (56978)
ALS (129)
Alzheimer's disease (1628)
Antibody-drug conjugate (ADC) (197)
Approvals (18210)
Artificial intelligence (433)
Autoimmune disease (39)
Automation (22)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (143)
Biotechnology (482)
Bladder cancer (110)
Brain cancer (45)
Breast cancer (420)
Cancer (3370)
Cardiovascular disease (273)
Career advice (3546)
Career pathing (34)
CAR-T (222)
CDC (43)
Cell therapy (611)
Cervical cancer (27)
Clinical research (74703)
Collaboration (1213)
Company closure (4)
Compensation (806)
Complete response letters (44)
COVID-19 (2926)
CRISPR (72)
C-suite (446)
Cystic fibrosis (128)
Data (3450)
Decentralized trials (2)
Denatured (57)
Depression (88)
Diabetes (396)
Diagnostics (7022)
Digital health (27)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (201)
Drug pricing (168)
Drug shortages (36)
Duchenne muscular dystrophy (174)
Earnings (98577)
Editorial (51)
Employer branding (25)
Employer resources (169)
Events (131926)
Executive appointments (938)
FDA (20353)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (1084)
Gene editing (155)
Generative AI (43)
Gene therapy (482)
GLP-1 (976)
Government (5325)
Grass and pollen (7)
Guidances (327)
Healthcare (20931)
HIV (47)
Huntington's disease (32)
IgA nephropathy (48)
Immunology and inflammation (201)
Immuno-oncology (17)
Indications (44)
Infectious disease (3136)
Inflammatory bowel disease (173)
Inflation Reduction Act (13)
Influenza (83)
Intellectual property (148)
Interviews (813)
IPO (17915)
IRA (59)
Job creations (5194)
Job search strategy (2863)
Kidney cancer (15)
Labor market (65)
Layoffs (615)
Leadership (29)
Legal (10143)
Liver cancer (88)
Longevity (12)
Lung cancer (472)
Lymphoma (240)
Machine learning (17)
Management (65)
Manufacturing (520)
MASH (113)
Medical device (14793)
Medtech (14806)
Mergers & acquisitions (22648)
Metabolic disorders (1024)
Multiple sclerosis (108)
NASH (23)
Neurodegenerative disease (170)
Neuropsychiatric disorders (49)
Neuroscience (2469)
NextGen: Class of 2025 (7687)
Non-profit (5094)
Now hiring (53)
Obesity (517)
Opinion (300)
Ovarian cancer (110)
Pain (139)
Pancreatic cancer (139)
Parkinson's disease (210)
Partnered (27)
Patents (367)
Patient recruitment (229)
Peanut (55)
People (65930)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (23041)
Phase II (32431)
Phase III (24423)
Pipeline (2325)
Policy (270)
Postmarket research (3554)
Preclinical (10402)
Press Release (72)
Prostate cancer (164)
Psychedelics (48)
Radiopharmaceuticals (279)
Rare diseases (579)
Real estate (7404)
Recruiting (76)
Regulatory (27517)
Reports (64)
Research institute (2668)
Resumes & cover letters (650)
Rett syndrome (11)
RNA editing (14)
RSV (62)
Schizophrenia (113)
Series A (180)
Series B (130)
Service/supplier (30)
Sickle cell disease (73)
Special edition (23)
Spinal muscular atrophy (168)
Sponsored (38)
Startups (4313)
State (2)
Stomach cancer (17)
Supply chain (89)
Tariffs (81)
The Weekly (101)
Vaccines (980)
Venture capital (62)
Weight loss (357)
Women's health (54)
Worklife (20)
Date
Today (116)
Last 7 days (481)
Last 30 days (2737)
Last 365 days (34054)
2025 (21946)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (75)
Alaska (7)
Arizona (289)
Arkansas (14)
Asia (50702)
Australia (8907)
California (8524)
Canada (2602)
China (793)
Colorado (364)
Connecticut (381)
Delaware (232)
Europe (116402)
Florida (1276)
Georgia (294)
Hawaii (3)
Idaho (67)
Illinois (775)
India (39)
Indiana (416)
Iowa (19)
Japan (255)
Kansas (120)
Kentucky (34)
Louisiana (20)
Maine (75)
Maryland (1181)
Massachusetts (6472)
Michigan (290)
Minnesota (526)
Mississippi (4)
Missouri (109)
Montana (32)
Nebraska (26)
Nevada (96)
New Hampshire (75)
New Jersey (2358)
New Mexico (31)
New York (2338)
North Carolina (1318)
North Dakota (10)
Northern California (3757)
Ohio (272)
Oklahoma (17)
Oregon (49)
Pennsylvania (1808)
Puerto Rico (18)
Rhode Island (42)
South America (1654)
South Carolina (42)
South Dakota (1)
Southern California (3207)
Tennessee (138)
Texas (1336)
United States (31883)
Utah (254)
Virginia (231)
Washington D.C. (81)
Washington State (735)
West Virginia (4)
Wisconsin (89)
There are 856,407 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Amylyx Axes Drug Program for Rare Neurodegenerative Disorder
AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year— was unable to distinguish itself from placebo in a mid-to-late-stage trial of progressive supranuclear palsy.
August 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Theralase(R) Releases 2Q2025 Financial Statements
August 27, 2025
·
1 min read
Press Releases
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA’s CNPV National Priority Initiative
August 27, 2025
·
6 min read
Press Releases
Generative AI in Personalized Medicine Market Size Worth USD 57.33 Billion by 2034 Driven by Rising Demand for Precision Therapies and Advanced AI Models
August 27, 2025
·
1 min read
Press Releases
CARTHERICS GRANTED CHINESE PATENT FOR ENHANCING IMMUNE CELL FUNCTION
August 27, 2025
·
1 min read
Press Releases
TrialAssure’s Zach Weingarden Joins Other Pharmaceutical Industry Leaders to Present on the Future of AI in Drug Development at RAPS Convergence 2025
August 27, 2025
·
1 min read
Neuroscience
Novartis, BioArctic Partner to Penetrate the Blood-Brain Barrier
Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a partnership with Eisai to produce Leqembi.
August 27, 2025
·
1 min read
·
Tristan Manalac
Rare diseases
Regeneron Eyes 2026 Filing For siRNA Myasthenia Gravis Drug After Phase III Win
Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities of daily living in patients with generalized myasthenia gravis.
August 27, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
Appia Shuts Down Before Reaching Clinic
Follow along as
BioSpace
tracks job cuts and restructuring initiatives throughout 2025.
August 27, 2025
·
191 min read
·
BioSpace Editorial Staff
Press Releases
Compass Pathways to Participate in Four Investor Conferences in September 2025
August 27, 2025
·
1 min read
1 of 85,641
Next
